Chargement en cours...

Biomarker predictors for immunotherapy benefit in breast: beyond PD-L1

PURPOSE OF REVIEW: Immune checkpoint blockade (ICB) has changed the clinical course of multiple cancer types and durable responses have now been observed in breast cancer (BC) patients. Most data suggest that, compared to other subtypes, triple-negative BC (TNBC) patients are more responsive to ICB,...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Curr Breast Cancer Rep
Auteurs principaux: James, Jamaal L., Balko, Justin M.
Format: Artigo
Langue:Inglês
Publié: 2019
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7731906/
https://ncbi.nlm.nih.gov/pubmed/33312343
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12609-019-00331-5
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!